dc.creator | ITURBE ESQUIVEL, BRANDON;#0000-0003-1518-8176 | |
dc.creator | Meneses Calderón, José;#0000-0001-6848-8434 | |
dc.creator | Concepción Carrillo, Luis Edgar;x1357352 | |
dc.creator | Mendieta Zerón, Hugo; 45175 | |
dc.creator | ITURBE ESQUIVEL, BRANDON | |
dc.creator | Meneses Calderón, José | |
dc.creator | Concepción Carrillo, Luis Edgar | |
dc.creator | Mendieta Zerón, Hugo | |
dc.date | 2022-07-05T02:58:58Z | |
dc.date | 2022-07-05T02:58:58Z | |
dc.date | 2022-05-30 | |
dc.date.accessioned | 2022-10-13T00:29:23Z | |
dc.date.available | 2022-10-13T00:29:23Z | |
dc.identifier | 1122-0643 | |
dc.identifier | http://hdl.handle.net/20.500.11799/113193 | |
dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/4156236 | |
dc.description | Combined treatments against SARS-CoV-2 are emerging and some have taken into account the post-COVID-19 fibrosis. The aim of this survey was to report the experience of treating COVID-19 patients with pirfenidone, nitazoxanide (NTZ) and colchicine. It was a case series report of COVID-19 patients treated from December 2020 to March 2021, in a rural health center located in the State of Mexico, Mexico. 23 patients were included (mean age 44.5 ± 17.1 years), 12 women (mean age 45.9 ± 17.9 years) and 11 men (mean age 43 ± 16.9 years) with four deaths (17.39%). The evolution time was of 17.3 ± 6.7 days being the main symptoms fever (82.6%), myalgia (69.6%) and cough (65.2%). The main comorbidities were overweight/obesity 18 (78.26%), type 2 diabetes mellitus (T2DM) 4 (17.39%), Chronic obstructive pulmonary disease (COPD) 5 (21.73%) and systemic hypertension 2 (8.69%). Two patients were intubated and both died; in these cases, they refused to take NTZ until after three days the medical doctor had prescribed it for the first time. It can be concluded that implementing a mixed treatment with pirfenidone, NTZ and colchicine could improve the survival rate in ambulatory patients of low socioeconomic status. | |
dc.language | eng | |
dc.publisher | PAGEPress srl, Italy | |
dc.rights | openAccess | |
dc.rights | http://creativecommons.org/licenses/by-nc-nd/4.0 | |
dc.rights | http://creativecommons.org/licenses/by-nc-nd/4.0 | |
dc.subject | COVID-19 | |
dc.subject | Pirfenidone | |
dc.subject | Nitazoxanide | |
dc.subject | Colchicine | |
dc.subject | MEDICINA Y CIENCIAS DE LA SALUD | |
dc.subject | MEDICINA Y CIENCIAS DE LA SALUD | |
dc.title | Rural treatment of COVID-19 patients with pirfenidone, nitazoxanide and colchicine. Case series | |
dc.type | Artículo | |
dc.type | article | |